Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 14;13(6):629-642.
doi: 10.1159/000539794. eCollection 2024 Dec.

LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B

Affiliations

LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B

Sungeun Park et al. Liver Cancer. .

Abstract

Introduction: The Liver Imaging Reporting and Data System (LI-RADS) categorization has been proposed as a potential prognostic indicator for primary liver neoplasms in patients with liver cirrhosis or chronic hepatitis B. This multicenter study aimed to determine whether LI-RADS categorization can offer additional post-surgical prognostic value for intrahepatic cholangiocarcinoma (ICCA) when used in conjunction with the American Joint Committee on Cancer (AJCC) guidelines.

Methods: Patients with high risk for hepatocellular carcinoma, surgically confirmed ICCAs, and available preoperative MRI were enrolled. LI-RADS categorization of ICCAs was performed using MRI features, and multivariate analyses were conducted incorporating LI-RADS category, AJCC staging, and clinicopathologic factors to evaluate their predictive value for postoperative recurrence-free survival (RFS) and overall survival (OS). In patients with early recurrence (<2 years), the percentages of AJCC stage I and LR-M or LR tumor-in-vein (TIV) were calculated, respectively.

Results: Among the 166 ICCAs analyzed, 13.3% (22/166) were classified as LR-4/5, 77.7% (129/166) as LR-M, and 9.0% (15/166) as LR TIV. Classifications according to the 8th AJCC guidelines for patients with available post-surgical pathologic data and follow-up imaging were 40.6% (63/155) stage I tumors, 23.9% (37/155) stage II, and 35.5% (55/155) stage III. Multivariate analysis revealed that LI-RADS category (LR-M or LR-TIV) was a significant factor for predicting both RFS (hazard ratio [HR] = 2.86, p = 0.02) and OS (HR = 3.18, p = 0.03). Additionally, AJCC staging (II or III) was a significant factor for RFS (HR = 3.90, p < 0.001) and OS (HR = 3.29, p < 0.001), male sex was a significant factor for RFS (HR = 1.89, p = 0.006) and OS (HR = 2.23, p = 0.002), and positive resection margin was a significant factor for OS (HR = 1.91, p = 0.03). Among the 80 patients with early recurrence, 97.5% displayed LR-M or LR-TIV features, while 11.3% were AJCC stage I patients.

Conclusion: The MRI-based preoperative LI-RADS categorization of ICCA provides additional post-surgical prognostic value beyond the AJCC guidelines, with significant implications for both RFS and OS.

Keywords: Cholangiocarcinoma; Liver Imaging Reporting and Data System; Magnetic resonance imaging; Recurrence; Survival.

PubMed Disclaimer

Conflict of interest statement

Corresponding author, Jeong Min Lee, is an editorial board member of Liver Cancer. Jeong Min Lee received grant from Samsung Medison, Siemens Healthineers, Philips Healthcare, GE Healthcare, Bayer, Guerbet, CMS, Canon Healthcare, and Dongkuk Pharma; payment for lectures from Samsung Medison, GE Healthcare, Philips Healthcare, and Starmed, outside the submitted work. The other authors have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
Flow diagram of patient enrollment.
Fig. 2.
Fig. 2.
Mass-forming intrahepatic cholangiocarcinoma in a 59-year-old man with chronic hepatitis B virus infection. a–c Gadoxetic acid-enhanced MRI shows a 4.5 cm rim arterial phase hyperenhancing mass (a, arrow) in segment IV with delayed central enhancement and peripheral washout (b, arrow). It also shows a targetoid hepatobiliary phase appearance (c, arrow). The lesion was TNM stage I (T1a, N0, M0), according to the AJCC 8th edition, whereas it was categorized into LI-RADS category M on gadoxetic acid-enhanced MRI. At 19 months after hepatic resection, the tumor recurred as lymph node metastases (d, arrows). This patient died 47 months after surgery.
Fig. 3.
Fig. 3.
Mass-forming intrahepatic cholangiocarcinoma in a 60-year-old man with chronic hepatitis B virus infection. a–c Gadoxetic acid-enhanced MRI shows a 1.9 cm non-rim arterial phase hyperenhancing mass (a, arrow) in segment VI with arterial corona enhancement and non-peripheral portal washout (b, arrow). It also shows a non-infiltrative appearance (c, arrow). The lesion was TNM stage I (T1a, N0, M0), according to the AJCC 8th edition, and was categorized into LI-RADS category 5 on gadoxetic acid-enhanced MRI. The tumor did not recur, and the patient survived for 55 months following the hepatic wedge resection (d, contrast-enhanced CT at 55 months after surgery).
Fig. 4.
Fig. 4.
Kaplan-Meier analyses of RFS and OS according to AJCC stage (a, b) and LI-RADS category (c, d).

Similar articles

Cited by

References

    1. Banales JM, Marin JJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88. - PMC - PubMed
    1. Liau JY, Tsai JH, Yuan RH, Chang CN, Lee HJ, Jeng YM. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod Pathol. 2014;27(8):1163–73. - PubMed
    1. Rhee H, Ko JE, Chung T, Jee BA, Kwon SM, Nahm JH, et al. . Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver Int. 2018;38(1):113–24. - PubMed
    1. Yu TH, Yuan RH, Chen YL, Yang WC, Hsu HC, Jeng YM. Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression. Mod Pathol. 2011;24(6):810–9. - PubMed
    1. Krasinskas AM. Cholangiocarcinoma. Surg Pathol Clin. 2018;11(2):403–29. - PubMed

LinkOut - more resources